3M Symposium educates clinicians on reducing complications in vascular access
25 June 2012
Complications associated with intravascular catheters are known to cause significant levels of patient morbidity and mortality. Data indicates that approximately 80 per cent of primary bacteraemia are related to the positioning of central venous catheters commonly used in treatment regimes in the ICU environment1. Many approaches have been taken to reduce the incidence and severity of catheter-related bloodstream infections, including the adoption of ‘bundles of care’, but the challenge remains. “The (identification of) predominant source of intravascular catheter-related bloodstream infections has been a research and clinical question for more than 30 years.” (Mermel 2011)2
Educating clinicians on current and most promising preventative strategies is, therefore, critical. This topic forms the key theme of a satellite symposium, organised by the Skin & Wound Care division of global technology company 3M, at the 2012 WoCoVa (World Congress on Vascular Access) Congress. Taking place in Amsterdam, the Netherlands, the symposium is chaired by Professor Tom Elliott, Consultant Microbiologist at University Hospital, Birmingham, United Kingdom, who has contributed over 300 publications to the understanding of the pathogenesis of device related sepsis.
Speaker Dr Mark Rupp, Professor in the Department of Internal Medicine at the University of Nebraska Medical Center, US, will address the clinical significance and pathogenesis of intravascular-catheter-related bloodstream infections and offer evidence-based best practice recommendations for their prevention. Fellow speaker Andrew Jackson, the first IV Nurse Consultant in the United Kingdom and originator of the ’Visual Infusion Phlebitis (VIP) Score’ tool,3 will examine seventeen years of experience of peripheral vascular access and discuss how innovation has transformed clinical outcome from a stance based on failure acceptance to an expectation of problem prevention.
“3M is committed to offering insight, education and solutions to the challenges of catheter-related bloodstream infections,” commented Cécile Hoehler, Business Manager for IV Site, 3M Skin & Wound Care Division, Europe. “This symposium, with its highly knowledgeable speakers, forms a key part of our partnership with hospitals across Europe and provides the ideal platform to share best practice and advances in technology with WoCoVa delegates”.
3M is a bronze sponsor and exhibitor at the 2012 WoCoVa conference and has a broad portfolio of IV site products, based on the trusted Tegaderm brand. Recent innovations include Tegaderm I.V. Advanced Securement dressing with comfort adhesive technology and Tegaderm CHG dressing which incorporates the powerful antimicrobial activity of Chlorhexidine Gluconate. Find out more from the Tegaderm IV Site Facebook page at www.facebook.com/3Mtegadermivsolutions.
Notes to Editors
1. For further information, please contact Rosalind Smith, Communications Manager, 3M on +44 (0) 1509 613009 firstname.lastname@example.org
2. 3M and Tegaderm are trademarks of the 3M Company.
3. The 3M Satellite Symposium is taking place on 28 June 18,00-1900, Veiling Zaal, 1st Floor, Amsterdam Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam, The Netherlands
5. WoCoVA was established in 2009 and brings vascular access professionals together from around the globe. The 2nd World Congress on Vascular Access in June 2012 highlights global vascular access issues, technology advances and evidence-based practice and provides networking opportunities for health care professionals interested in the field of short and long term venous access. www.wocova.com/
3M Media enquires